Drug intelligence / Profile preview

anti-CD24 lentivirus

Development stage
Unknown
Lead developer
Sigma Aldrich
Modality
Gene Therapies
Administration
Intratumoral, Intravenous
01

Overview

Anti-CD24 lentivirus refers to a lentiviral vector system designed to target or modulate the CD24 (Cluster of Differentiation 24) antigen. CD24 is a glycosylphosphatidylinositol-anchored surface protein often overexpressed in various cancers and associated with cancer stem cell properties, metastasis, and immune evasion. These lentiviral constructs are primarily utilized in research settings to either deliver short hairpin RNA (shRNA) for CD24 gene silencing or to express anti-CD24 chimeric antigen receptors (CARs) in T cells for the development of CAR-T cell therapies. As a gene delivery platform, it enables the study of CD24's role in tumor progression and serves as a critical component in the engineering of targeted immunotherapies.

Other names
CD24 lentiviral vectorCD-24 lentiviral vectorCD 24 lentiviral vectorLentiviral-anti-CD24Lentiviral-anti-CD-24Lentiviral-anti-CD 24anti-CD24 shRNA lentivirusanti-CD-24 shRNA lentivirusanti-CD 24 shRNA lentivirusLentiviral vector-mediated CD24 gene silencing
02

Targets

CD24 (Cluster of Differentiation 24)

Beyond the preview

Go deeper on anti-CD24 lentivirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD24 lentivirus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call